At present, only 11 therapeutic choices against melanoma have been approved for clinical use, including BRAF and MEK inhibitors and therapeutic immune checkpoint inhibitors as well as IL-2 or Interferon alpha (Table 1). This evidence concerns the gene IL2 and melanoma.